BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Study to Evaluate the Effect of Six Cycles of Treatment With a Combined Oral Contraceptive (EE 0.30 mg/DRSP 3 mg) on Quality of Life.
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-08-22
- Last Posted Date
- 2013-10-11
- Lead Sponsor
- Bayer
- Target Recruit Count
- 221
- Registration Number
- NCT00367276
Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). A Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement.
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-08-09
- Last Posted Date
- 2014-10-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 2531
- Registration Number
- NCT00361894
Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-08-09
- Last Posted Date
- 2014-11-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 3148
- Registration Number
- NCT00362232
Study in Women With Idiopathic Menorrhagia to Determine the Reduction in Menstrual Blood Loss (MBL) After Treatment With the Levonorgestrel-releasing Intrauterine System (IUS)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-08-04
- Last Posted Date
- 2013-12-09
- Lead Sponsor
- Bayer
- Target Recruit Count
- 165
- Registration Number
- NCT00360490
A Study of a New Chemotherapy Agent in Combination With Cisplatin to Treat Small Cell Lung Cancer
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-08-02
- Last Posted Date
- 2014-11-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 26
- Registration Number
- NCT00359359
Safety/Efficacy Study of Drospirenone/Estradiol to Treat Postmenopausal Chinese Women With Vasomotor Symptoms.
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-07-26
- Last Posted Date
- 2014-10-01
- Lead Sponsor
- Bayer
- Target Recruit Count
- 249
- Registration Number
- NCT00356447
Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib
Phase 4
Terminated
- Conditions
- Interventions
- First Posted Date
- 2006-07-17
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 2
- Registration Number
- NCT00352859
ZK-Epo Given With Prednisone in Patients With Metastatic Androgen-independent Prostate Cancer
- First Posted Date
- 2006-07-10
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 53
- Registration Number
- NCT00350051
BAY88-8223, Dose Finding Study in Patients With HRPC
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-06-15
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 122
- Registration Number
- NCT00337155
Fat Distribution in Healthy Early Postmenopausal Women
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-06-09
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 67
- Registration Number
- NCT00335218
© Copyright 2024. All Rights Reserved by MedPath